RESUMO
OBJECTIVE: Bone morphogenetic protein (BMP) is a growth factor that aids in osteoinduction and promotes bone fusion. There is a lack of literature regarding recombinant human BMP-2 (rhBMP-2) dosage in different spine surgeries. This study aims to investigate the trends in rhBMP-2 dosage and the associated complications in spinal arthrodesis. METHODS: A retrospective study was conducted investigating spinal arthrodesis using rhBMP-2. Variables including age, procedure type, rhBMP-2 size, complications, and postoperative imaging were collected. Cases were grouped into the following surgical procedures: anterior lumbar interbody fusion/extreme lateral interbody fusion (ALIF/XLIF), posterior lumbar interbody fusion/transforaminal lumbar interbody fusion (PLIF/TLIF), posterolateral fusion (PLF), anterior cervical discectomy and fusion (ACDF), and posterior cervical fusion (PCF). RESULTS: A total of 1209 patients who received rhBMP-2 from 2006 to 2020 were studied. Of these, 230 were categorized as ALIF/XLIF, 336 as PLIF/TLIF, 243 as PLF, 203 as ACDF, and 197 as PCF. PCF (P < 0.001), PLIF/TLIF (P < 0.001), and PLF (P < 0.001) demonstrated a significant decrease in the rhBMP-2 dose used per level, with major transitions seen in 2018, 2011, and 2013, respectively. In our sample, 129 complications following spinal arthrodesis were noted. A significant relation between rhBMP-2 size and complication rates (χ2= 73.73, P = 0.0029) was noted. rhBMP-2 dosage per level was a predictor of complication following spinal arthrodesis (odds ratio = 1.302 [1.05-1.55], P < 0.001). CONCLUSIONS: BMP is an effective compound in fusing adjacent spine segments. However, it carries some regional complications. We demonstrate a decreasing trend in the dose/vertebral level. A decrease rhBMP-2 dose per level correlated with a decrease in complication rates.
Assuntos
Proteína Morfogenética Óssea 2/administração & dosagem , Complicações Pós-Operatórias/prevenção & controle , Doenças da Coluna Vertebral/tratamento farmacológico , Doenças da Coluna Vertebral/cirurgia , Fusão Vertebral/tendências , Fator de Crescimento Transformador beta/administração & dosagem , Proteína Morfogenética Óssea 2/efeitos adversos , Estudos de Coortes , Discotomia/efeitos adversos , Discotomia/tendências , Relação Dose-Resposta a Droga , Humanos , Estudos Longitudinais , Complicações Pós-Operatórias/induzido quimicamente , Complicações Pós-Operatórias/etiologia , Proteínas Recombinantes/administração & dosagem , Proteínas Recombinantes/efeitos adversos , Estudos Retrospectivos , Fusão Vertebral/efeitos adversos , Fator de Crescimento Transformador beta/efeitos adversosRESUMO
BACKGROUND CONTEXT: The effects of using off-label recombinant human bone morphogenetic protein (rhBMP)-2 for interbody fusion are controversial. Although animal models of posterolateral fusion are well-established, establishing animal models to validate the safety and efficacy of interbody fusion is difficult, which may contribute to the inconsistent clinical results. PURPOSE: To develop a novel animal model of interbody fusion in rat coccygeal vertebrae without destroying bony endplates. STUDY DESIGN: An experimental animal study. METHODS: Forty-five male Sprague-Dawley rats underwent coccygeal interbody fusion without violating vertebral endplates. The animals were divided into three different groups based on the materials that were implanted into the interbody space (1) allogeneic iliac bone (IB) alone (IB group), (2) IB and 3 µg of rhBMP-2 (BMP low-dose group), or (3) IB and 10 µg of rhBMP-2 (BMP high-dose group). Fusion rates were investigated using microcomputed tomography 6 weeks after the operation. The incidence of adverse events, including soft-tissue swelling, delayed wound healing, osteolysis, and ectopic bone formation were evaluated. The total number of adverse events (using the adverse event score) in each group and the swelling ratio (calculated using the surgical site tissue volume [TV; TV on postoperative day 1/preoperative TV]) were also evaluated. RESULTS: The fusion rates in the BMP low- and high-dose groups (33.3% and 46.7%) were not significantly different, but both were significantly higher than that in the IB group (0%) (p=.042 and .006, respectively). Significant differences in the incidence of osteolysis, adverse event scores, and swelling ratios were observed only between the BMP high-dose and IB groups (p=.043, .006 and .014, respectively). CONCLUSIONS: We developed a novel rat model of interbody fusion in which the vertebral endplates were not violated, reflecting the normal clinical setting. rhBMP-2 use increased the fusion rate, but a higher dose of rhBMP-2 did not lead to a higher fusion rate than that for low-dose rhBMP-2; conversely, it led to an increase in the occurrence of adverse events. CLINICAL SIGNIFICANCE: This novel rat model of coccygeal interbody fusion that preserved bony endplates has clinical significance for validating the effectiveness of biologics or bone graft substitutes before clinical trial.
Assuntos
Fusão Vertebral , Animais , Proteína Morfogenética Óssea 2 , Ílio , Vértebras Lombares , Masculino , Ratos , Ratos Sprague-Dawley , Proteínas Recombinantes , Fusão Vertebral/efeitos adversos , Fator de Crescimento Transformador beta/efeitos adversos , Microtomografia por Raio-XRESUMO
BACKGROUND: The U.S. Food and Drug Administration reported a higher incidence of cancer in patients who had spinal arthrodesis and were exposed to a high dose of recombinant human bone morphogenetic protein-2 (rhBMP-2) compared with the control group in a randomized controlled trial. The purpose of this study was to determine the risk of cancer after spinal arthrodesis with BMP. METHODS: We retrospectively analyzed the incidence of cancer in 467,916 Medicare patients undergoing spinal arthrodesis from 2005 to 2010. Patients with a preexisting diagnosis of cancer were excluded. The average follow-up duration was 2.85 years for the BMP group and 2.94 years for the control group. The main outcome measure was the relative risk of developing new malignant lesions after spinal arthrodesis with or without exposure to BMP. RESULTS: The relative risk of developing cancer after BMP exposure was 0.938 (95% confidence interval [95% CI]: 0.913 to 0.964), which was significant. In the BMP group, 5.9% of the patients developed an invasive cancer compared with 6.5% of the patients in the control group. The relative risk of developing cancer after BMP exposure was 0.98 in males (95% CI: 0.94 to 1.02) and 0.93 (95% CI: 0.90 to 0.97) in females. The control group showed a higher incidence of each type of cancer except pancreatic cancer. CONCLUSIONS: Recent clinical use of BMP was not associated with a detectable increase in the risk of cancer within a mean 2.9-year time window. LEVEL OF EVIDENCE: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.
Assuntos
Proteínas Morfogenéticas Ósseas/efeitos adversos , Neoplasias/etiologia , Doenças da Coluna Vertebral/tratamento farmacológico , Fusão Vertebral/métodos , Distribuição por Idade , Idoso , Idoso de 80 Anos ou mais , Proteína Morfogenética Óssea 2/efeitos adversos , Proteína Morfogenética Óssea 2/uso terapêutico , Proteínas Morfogenéticas Ósseas/uso terapêutico , Estudos de Casos e Controles , Intervalos de Confiança , Relação Dose-Resposta a Droga , Esquema de Medicação , Feminino , Seguimentos , Humanos , Incidência , Masculino , Medicare/estatística & dados numéricos , Pessoa de Meia-Idade , Neoplasias/epidemiologia , Neoplasias/patologia , Valor Preditivo dos Testes , Proteínas Recombinantes/efeitos adversos , Proteínas Recombinantes/uso terapêutico , Estudos Retrospectivos , Medição de Risco , Programa de SEER , Distribuição por Sexo , Doenças da Coluna Vertebral/cirurgia , Fusão Vertebral/efeitos adversos , Fatores de Tempo , Fator de Crescimento Transformador beta/efeitos adversos , Fator de Crescimento Transformador beta/uso terapêutico , Resultado do Tratamento , Estados Unidos/epidemiologiaRESUMO
BACKGROUND: Since the introduction of rhBMP-2 (Infuse) in 2002, surgeons have had an alternative substitute to autograft and its related donor site morbidity. Recently, the prevalence of reported adverse events and complications related to the use of rhBMP-2 has raised many ethical and legal concerns for surgeons. Additionally, the cost and decreasing reimbursement landscape of rhBMP-2 use have required identification of a viable alternative. Osteo allogeneic morphogenetic protein (OsteoAMP) is a commercially available allograft-derived growth factor rich in osteoinductive, angiogenic, and mitogenic proteins. This study compares the radiographic fusion outcomes between rhBMP-2 and OsteoAMP allogeneic morphogenetic protein in lumbar interbody fusion spine procedures. METHODS: Three hundred twenty-one (321) patients from three centers underwent a transforaminal lumbar interbody fusion (TLIF) or lateral lumbar interbody fusion (LLIF) procedure and were assessed by an independent radiologist for fusion and radiographically evident complications. The independent radiologist was blinded to the intervention, product, and surgeon information. Two hundred and twenty-six (226) patients received OsteoAMP with autologous local bone, while ninety-five (95) patients received Infuse with autologous local bone. Patients underwent radiographs (x-ray and/or CT) at standard postoperative follow-up intervals of approximately 1, 3, 6, 12, and 18 months. Fusion was defined as radiographic evidence of bridging across endplates, or bridging from endplates to interspace disc plugs. Osteobiologic surgical supply costs were also analyzed to ascertain cost differences between OsteoAMP and rhBMP-2. RESULTS: OsteoAMP produced higher rates of fusion at 6, 12, and 18 months (p ≤ 0.01). The time required for OsteoAMP to achieve fusion was approximately 40% less than rhBMP-2 with approximately 70% fewer complications. Osteobiologic supply costs were 80.5% lower for OsteoAMP patients (73.7% lower per level) than for rhBMP-2. CONCLUSIONS: Results of this study indicate that OsteoAMP is a viable alternative to rhBMP-2 both clinically and economically when used in TLIF and LLIF spine procedures.
Assuntos
Proteínas Morfogenéticas Ósseas/uso terapêutico , Vértebras Lombares/cirurgia , Fusão Vertebral/métodos , Adulto , Idoso , Proteína Morfogenética Óssea 2/efeitos adversos , Proteína Morfogenética Óssea 2/economia , Proteína Morfogenética Óssea 2/uso terapêutico , Proteínas Morfogenéticas Ósseas/efeitos adversos , Proteínas Morfogenéticas Ósseas/economia , Transplante Ósseo/métodos , Custos de Medicamentos/estatística & dados numéricos , Avaliação de Medicamentos/métodos , Feminino , Humanos , Vértebras Lombares/diagnóstico por imagem , Masculino , Pessoa de Meia-Idade , Ossificação Heterotópica/induzido quimicamente , Osteólise/induzido quimicamente , Radiografia , Proteínas Recombinantes/efeitos adversos , Proteínas Recombinantes/economia , Proteínas Recombinantes/uso terapêutico , Estudos Retrospectivos , Método Simples-Cego , Fusão Vertebral/efeitos adversos , Fator de Crescimento Transformador beta/efeitos adversos , Fator de Crescimento Transformador beta/economia , Fator de Crescimento Transformador beta/uso terapêutico , Resultado do TratamentoRESUMO
BACKGROUND CONTEXT: Recent reports of postoperative radiculitis, bone osteolysis, and symptomatic ectopic bone formation after recombinant human bone morphogenetic protein-2 (rhBMP-2) use in transforaminal lumbar interbody fusions (TLIFs) are a cause for concern. PURPOSE: To determine the clinical and radiographic complications associated with BMP utilization in a minimally invasive transforaminal lumbar interbody fusion (MIS-TLIF) environment. STUDY DESIGN/SETTING: Retrospective clinical case series at a single institution. PATIENT SAMPLE: Five hundred seventy-three consecutive patients undergoing an MIS-TLIF. OUTCOME MEASURES: Reoperation rates and total costs associated with complications of rhBMP-2 use and pseudarthrosis. METHODS: A retrospective review of 610 consecutive patients undergoing an MIS-TLIF (2007-2010) by a single surgeon at our institution was performed (mean age 48.7 years, range 26-82 years). All patients underwent an MIS laminectomy with bilateral facetectomy, single TLIF cage, unilateral pedicle screw fixation, and 12 mg (large kit) or 4.2 mg (small kit) of rhBMP-2. The BMP-2 collagen-soaked sponge was placed anteriorly in the disc space, followed by local bone graft, and then the cage was filled only with local bone and no BMP-2. Patients were evaluated at 6 months and 1 year with computed tomography (CT) scan. Those demonstrating neuroforaminal bone growth, osteolysis/cage migration, or pseudarthrosis were reviewed, and cost data including direct cost/procedure for both index and revision surgeries were collected. RESULTS: Of the 573 patients, 10 (1.7%) underwent 15 additional procedures based on recalcitrant radiculopathy and CT evidence of neuroforaminal bone growth, vertebral body osteolysis, and/or cage migration. Thirty-nine patients (6.8%) underwent reoperation for clinically symptomatic pseudarthrosis. Bone overgrowth was associated with nerve impingement and radiculopathy in all 10 patients (small kit, n=9; large kit, n=1). Osteolysis and cage migration occurred in 2 (20%) of these same 10 patients. Average total costs were calculated per procedure ($19,224), and the costs for reoperation equaled $14,785 per encounter for neuroforaminal bone growth and $20,267 for pseudarthrosis. CONCLUSIONS: Symptomatic ectopic bone formation, vertebral osteolysis, and pseudarthrosis are recognized complications with the use of rhBMP-2 in MIS-TLIFs. Potential causes include improper dosage and a closed space that prevents the egress of the postoperative BMP-2 fluid collection. Management of these complications has a substantial cost for the patient and the surgeon and needs to be considered with the off-label use of rhBMP-2.
Assuntos
Proteína Morfogenética Óssea 2/efeitos adversos , Procedimentos Cirúrgicos Minimamente Invasivos , Complicações Pós-Operatórias/epidemiologia , Reoperação/economia , Fusão Vertebral/efeitos adversos , Fusão Vertebral/métodos , Fator de Crescimento Transformador beta/efeitos adversos , Adulto , Idoso , Idoso de 80 Anos ou mais , Proteína Morfogenética Óssea 2/economia , Feminino , Humanos , Vértebras Lombares , Masculino , Pessoa de Meia-Idade , Procedimentos Cirúrgicos Minimamente Invasivos/efeitos adversos , Complicações Pós-Operatórias/economia , Proteínas Recombinantes/efeitos adversos , Proteínas Recombinantes/economia , Reoperação/estatística & dados numéricos , Estudos Retrospectivos , Fusão Vertebral/economia , Fator de Crescimento Transformador beta/economiaAssuntos
Acesso à Informação , Proteína Morfogenética Óssea 2/uso terapêutico , Fator de Crescimento Transformador beta/uso terapêutico , Proteína Morfogenética Óssea 2/efeitos adversos , Transplante Ósseo/efeitos adversos , Transplante Ósseo/métodos , Indústria Farmacêutica , Humanos , Proteínas Recombinantes/efeitos adversos , Proteínas Recombinantes/uso terapêutico , Literatura de Revisão como Assunto , Fusão Vertebral , Fator de Crescimento Transformador beta/efeitos adversos , Estados UnidosRESUMO
OBJECTIVE: To investigate whether published results of industry funded trials of recombinant human bone morphogenetic protein 2 (rhBMP-2) in spinal fusion match underlying trial data by comparing three different data sources: individual participant data, internal industry reports, and publicly available journal publications and conference abstracts. DATA COLLECTION AND SYNTHESIS: The manufacturer of rhBMP-2 products (Medtronic; Minneapolis, MN) provided complete individual participant data and internal reports for all its studies of rhMBP-2 in spinal fusion. We identified publications and conference abstracts through comprehensive literature searches. We compared outcomes provided in the individual participant data against outcomes reported in publications. For effectiveness outcomes, we compared meta-analyses of randomised controlled trials based on each of the three data sources. For adverse events, meta-analysis of the published aggregate data was not possible and we compared the number and type of adverse events reported between data sources. RESULTS: 32 publications reported outcomes from 11 of the 17 existing manufacturer sponsored studies. For individual randomised controlled trials, 56% (9/16) to 88% (15/17) of effectiveness outcomes known to have been collected were reported in the published literature. Meta-analyses of effectiveness data were almost identical for pain outcomes and similar for fusion across the three data sources. A minority of adverse event data known to have been collected were reported in the published literature. Several journal articles reported only "serious," "related," or "unanticipated" adverse events, without defining these terms. Others reported a small proportion of the collected adverse event categories. Around 23% (533/2302) of the total adverse events collected in published randomised controlled trials have been reported in the literature, with randomised controlled trials evaluating the licensed preparation (Infuse) reporting around 11% (122/1108) of collected adverse events. CONCLUSIONS: The published literature only partially represents the total data known to have been collected on the effects of rhBMP-2. This did not lead to substantially different results for meta-analysis of effectiveness outcomes. In contrast, reporting of adverse event data in trial publications was inadequate and inconsistent to the extent that any systematic review based solely on the publicly available data would not be able to properly evaluate the safety of rhBMP-2. Analysis of individual participant data enabled the most complete, detailed, and in-depth analysis and was not more resource intensive than extracting, collating, and analysing aggregate data from multiple trial publications and conference abstracts. Confidential internal reports presented considerably more adverse event data than publications, and in the absence of individual participant data access to these reports would support more accurate and reliable investigation, with less time and effort than relying on incomplete published data.
Assuntos
Sistemas de Notificação de Reações Adversas a Medicamentos/organização & administração , Proteína Morfogenética Óssea 2 , Avaliação de Processos e Resultados em Cuidados de Saúde , Projetos de Pesquisa/normas , Fusão Vertebral , Fator de Crescimento Transformador beta , Proteína Morfogenética Óssea 2/administração & dosagem , Proteína Morfogenética Óssea 2/efeitos adversos , Indústria Farmacêutica/economia , Indústria Farmacêutica/métodos , Humanos , Metanálise como Assunto , Avaliação de Processos e Resultados em Cuidados de Saúde/métodos , Avaliação de Processos e Resultados em Cuidados de Saúde/normas , Avaliação de Processos e Resultados em Cuidados de Saúde/estatística & dados numéricos , Medição da Dor/estatística & dados numéricos , Dor Pós-Operatória/diagnóstico , Dor Pós-Operatória/epidemiologia , Ensaios Clínicos Controlados Aleatórios como Assunto , Proteínas Recombinantes/administração & dosagem , Proteínas Recombinantes/efeitos adversos , Apoio à Pesquisa como Assunto , Fusão Vertebral/efeitos adversos , Fusão Vertebral/métodos , Fusão Vertebral/estatística & dados numéricos , Análise de Sistemas , Fator de Crescimento Transformador beta/administração & dosagem , Fator de Crescimento Transformador beta/efeitos adversos , Resultado do TratamentoRESUMO
BACKGROUND: Recombinant human bone morphogenetic protein-2 (rhBMP-2) is used as a bone graft substitute in spinal fusion, which unites (fuses) bones in the spine. The accuracy and completeness of journal publications of industry-sponsored trials on the effectiveness and harms of rhBMP-2 has been called into question. PURPOSE: To independently assess the effectiveness and harms of rhBMP-2 in spinal fusion and reporting bias in industry-sponsored journal publications. DATA SOURCES: Individual-patient data (IPD) from 17 industry-sponsored studies; related internal documents; and searches of MEDLINE (1996 to August 2012), other databases, and reference lists. STUDY SELECTION: Randomized, controlled trials (RCTs) and cohort studies of rhBMP-2 versus any control and uncontrolled studies of harms. DATA EXTRACTION: Effectiveness outcomes in IPD were recalculated using consistent definitions. Study characteristics and results were abstracted by 1 investigator and confirmed by another. Two investigators independently assessed quality using predefined criteria. DATA SYNTHESIS: Thirteen RCTs and 31 cohort studies were included. For lumbar spine fusion, rhBMP-2 and iliac crest bone graft were similar in overall success, fusion, and other effectiveness measures and in risk for any adverse event, although rates were high across interventions (77% to 93% at 24 months from surgery). For anterior lumbar interbody fusion, rhBMP-2 was associated with nonsignificantly increased risk for retrograde ejaculation and urogenital problems. For anterior cervical spine fusion, rhBMP-2 was associated with increased risk for wound complications and dysphagia. At 24 months, the cancer risk was increased with rhBMP-2 (risk ratio, 3.45 [95% CI, 1.98 to 6.00]), but event rates were low and cancer was heterogeneous. Early journal publications misrepresented the effectiveness and harms through selective reporting, duplicate publication, and underreporting. LIMITATIONS: Outcome assessment was not blinded, and ascertainment of harms in trials was poor. No trials were truly independent of industry sponsorship. CONCLUSION: In spinal fusion, rhBMP-2 has no proven clinical advantage over bone graft and may be associated with important harms, making it difficult to identify clear indications for rhBMP-2. Earlier disclosure of all relevant data would have better informed clinicians and the public than the initial published trial reports did. PRIMARY FUNDING SOURCE: Yale University and Medtronic.
Assuntos
Proteína Morfogenética Óssea 2/efeitos adversos , Proteína Morfogenética Óssea 2/uso terapêutico , Conflito de Interesses , Indústria Farmacêutica , Degeneração do Disco Intervertebral/cirurgia , Viés de Publicação , Fusão Vertebral , Fator de Crescimento Transformador beta/efeitos adversos , Fator de Crescimento Transformador beta/uso terapêutico , Humanos , Ílio/transplante , Incidência , Neoplasias/epidemiologia , Uso Off-Label , Editoração/normas , Proteínas Recombinantes/efeitos adversos , Proteínas Recombinantes/uso terapêutico , Fusão Vertebral/métodos , Resultado do TratamentoAssuntos
Proteína Morfogenética Óssea 2/efeitos adversos , Proteína Morfogenética Óssea 2/uso terapêutico , Conflito de Interesses , Indústria Farmacêutica , Degeneração do Disco Intervertebral/cirurgia , Viés de Publicação , Fusão Vertebral , Fator de Crescimento Transformador beta/efeitos adversos , Fator de Crescimento Transformador beta/uso terapêutico , Humanos , Proteínas Recombinantes/efeitos adversos , Proteínas Recombinantes/uso terapêuticoAssuntos
Proteína Morfogenética Óssea 2/efeitos adversos , Proteína Morfogenética Óssea 2/uso terapêutico , Conflito de Interesses , Indústria Farmacêutica , Degeneração do Disco Intervertebral/cirurgia , Viés de Publicação , Fusão Vertebral , Fator de Crescimento Transformador beta/efeitos adversos , Fator de Crescimento Transformador beta/uso terapêutico , Humanos , Proteínas Recombinantes/efeitos adversos , Proteínas Recombinantes/uso terapêuticoAssuntos
Proteína Morfogenética Óssea 2/efeitos adversos , Proteína Morfogenética Óssea 2/uso terapêutico , Conflito de Interesses , Indústria Farmacêutica , Degeneração do Disco Intervertebral/cirurgia , Viés de Publicação , Fusão Vertebral , Fator de Crescimento Transformador beta/efeitos adversos , Fator de Crescimento Transformador beta/uso terapêutico , Humanos , Proteínas Recombinantes/efeitos adversos , Proteínas Recombinantes/uso terapêuticoAssuntos
Proteína Morfogenética Óssea 2/efeitos adversos , Proteína Morfogenética Óssea 2/uso terapêutico , Conflito de Interesses , Indústria Farmacêutica , Degeneração do Disco Intervertebral/cirurgia , Viés de Publicação , Fusão Vertebral , Fator de Crescimento Transformador beta/efeitos adversos , Fator de Crescimento Transformador beta/uso terapêutico , Humanos , Proteínas Recombinantes/efeitos adversos , Proteínas Recombinantes/uso terapêuticoRESUMO
STUDY DESIGN: This was a prospective study evaluating the incidence of retrograde ejaculation (RE) after anterior lumbar interbody fusion (ALIF) based on laboratory analysis of semen and urine. OBJECTIVE: The purpose of this study was to investigate the incidence of RE based on quantitative semen analysis and to compare the rate with that identified using a standardized qualitative questionnaire administered by telephone. SUMMARY OF BACKGROUND DATA: RE is a specific sexual dysfunction in which semen passes into the bladder during ejaculation. It has long been a known possible complication of ALIF associated with injury to the superior hypogastric plexus occurring during access to the anterior lumbar spine. Although reported in multiple studies, there is no standardized assessment for RE and many studies do not describe the methods by which it was assessed. Recently, there has been increased interest in ALIF-related RE with respect to the use of recombinant human bone morphogenetic protein (rhBMP-2). However, how RE was diagnosed remains loosely defined. One possible assessment of RE is to analyze semen and urine after ejaculation. METHODS: Forty-one male patients undergoing ALIF with posterior pedicle screw instrumentation and fusion at L4-L5 and/or L5-L1 consented to participate in the study. The subjects went to a cryobank for preoperative semen and postejaculatory urine analysis. They returned to the cryobank 3 to 6 months after surgery for repeat testing. The semen analysis consisted of ejaculate volume, total sperm count, concentration, and motility, whereas the urine test reported postejaculatory voided urine for spermatozoa. Postoperatively, patients were called by the principle investigator who conducted an interview based on a standardized questionnaire (completed for 36 patients). Patients were considered to have RE based on the questionnaire if they reported less or no ejaculate fluid. These results were compared with those from the laboratory testing to evaluate the value of the questionnaire in assessing RE. rhBMP-2 was used in 21 of the cases. The incidence of RE was compared in these patients versus those in whom rhBMP-2 was not used. RESULTS: Four patients (9.8%) were diagnosed with RE based on the laboratory analysis, 2 of which resolved spontaneously. Based on the questionnaire, 15 (41.7%) patients reported having RE, including the 4 that were confirmed by laboratory testing. Of the 21 patients treated with rhBMP-2, 2 (9.5%) were diagnosed with RE, 1 of which resolved. Of the 20 patients treated without rhBMP-2, 2 (10.0%) had RE, 1 of which resolved. CONCLUSION: This study suggests that use of a questionnaire tends to overestimate the incidence of RE as compared with the quantitative semen and urine analysis. Contrary to recent studies using retrospective qualitative review, in this small group with quantitative analysis, use of rhBMP-2 was not related to an increased incidence of RE, with a rate of approximately 10% in both patients receiving, and those not receiving, rhBMP-2. Further study of a larger group using preoperative semen and urine analysis, postoperative standard questionnaire and postoperative semen analysis should be pursued to further investigate the occurrence of RE and to possibly assist in developing and validating a questionnaire for RE assessment.
Assuntos
Proteína Morfogenética Óssea 2/efeitos adversos , Ejaculação/efeitos dos fármacos , Análise do Sêmen/métodos , Disfunções Sexuais Fisiológicas/etiologia , Inquéritos e Questionários/normas , Fator de Crescimento Transformador beta/efeitos adversos , Adulto , Ejaculação/fisiologia , Humanos , Vértebras Lombares/cirurgia , Masculino , Pessoa de Meia-Idade , Complicações Pós-Operatórias/etiologia , Complicações Pós-Operatórias/fisiopatologia , Complicações Pós-Operatórias/urina , Estudos Prospectivos , Proteínas Recombinantes/efeitos adversos , Reprodutibilidade dos Testes , Disfunções Sexuais Fisiológicas/fisiopatologia , Disfunções Sexuais Fisiológicas/urina , Contagem de Espermatozoides , Motilidade dos Espermatozoides , Fusão Vertebral/efeitos adversos , Fusão Vertebral/instrumentação , Fatores de Tempo , Adulto JovemAssuntos
Proteína Morfogenética Óssea 2 , Fusão Vertebral , Fator de Crescimento Transformador beta , Proteína Morfogenética Óssea 2/administração & dosagem , Proteína Morfogenética Óssea 2/efeitos adversos , Ensaios Clínicos como Assunto , Conflito de Interesses , Humanos , Publicações Periódicas como Assunto , Proteínas Recombinantes/administração & dosagem , Proteínas Recombinantes/efeitos adversos , Apoio à Pesquisa como Assunto , Fusão Vertebral/métodos , Fator de Crescimento Transformador beta/administração & dosagem , Fator de Crescimento Transformador beta/efeitos adversos , Resultado do TratamentoRESUMO
BACKGROUND: Using bone morphogenic protein (BMP) to augment fusion in spine surgery is widespread and lends itself in particular to minimally invasive lumbar fusion, where the surface area for fusion is significantly less than the equivalent open procedure. PURPOSE: Here we described the use of very low-dose BMP in promoting fusion in minimally invasive lumbar interbody fixation but also highlight some of the potential complications of BMP-2 use and techniques available to reduce or avoid them. STUDY DESIGN: Prospective observational study of consecutive patients undergoing minimally invasive lumbar interbody fusion with percutaneous pedicle screws. PATIENT SAMPLE: Thirty patients aged between 22 and 78 years (mean 53 years). OUTCOME MEASURES: Thin-slice lumbar computed tomography scanning with multiplanar reconstruction at 6 and 12 months postoperative. METHODS: Thirty-six spinal levels were instrumented in total, of which four underwent posterior lumbar interbody fusion and 32 underwent transforaminal lumbar interbody fusion. Bone graft harvested locally was placed in the disc space with low-dose BMP-2 (1.4 mg per level). RESULTS: Thirty-three of 36 spinal levels showed complete fusion at a mean postoperative scan time of 7.1 months. Two levels demonstrated partial fusion at 6 months, which was complete at 12 months. There was one case of nonunion at 12 months, which also demonstrated vertebral body osteolysis. Despite very low-dose BMP-2, two cases of asymptomatic heterotopic ossification were observed, and there were two cases of perineural cyst formation, one of whom required revision of the interbody cage. CONCLUSIONS: The use of BMP with autograft in the disc space during minimally invasive lumbar interbody fusion is associated with a high rate of early fusion. Even with very low-dose BMP used in this study, complications related to BMP usage were not avoided completely.
Assuntos
Proteína Morfogenética Óssea 2/efeitos adversos , Complicações Pós-Operatórias/patologia , Fusão Vertebral/métodos , Fator de Crescimento Transformador beta/efeitos adversos , Adulto , Idoso , Cistos/induzido quimicamente , Cistos/epidemiologia , Cistos/patologia , Feminino , Humanos , Vértebras Lombares , Masculino , Pessoa de Meia-Idade , Ossificação Heterotópica/induzido quimicamente , Ossificação Heterotópica/epidemiologia , Ossificação Heterotópica/patologia , Osteólise/induzido quimicamente , Osteólise/epidemiologia , Osteólise/patologia , Complicações Pós-Operatórias/induzido quimicamente , Complicações Pós-Operatórias/epidemiologia , Proteínas Recombinantes/efeitos adversos , Fusão Vertebral/efeitos adversos , Resultado do Tratamento , Adulto JovemAssuntos
Antineoplásicos/efeitos adversos , Antineoplásicos/farmacologia , Indústria Farmacêutica/tendências , Neoplasias/tratamento farmacológico , Fator de Crescimento Transformador beta/efeitos adversos , Fator de Crescimento Transformador beta/antagonistas & inibidores , Animais , Anticorpos Monoclonais/farmacologia , Proliferação de Células/efeitos dos fármacos , Ensaios Clínicos como Assunto/tendências , Terapia Combinada , Humanos , Imunoterapia/métodos , Camundongos , Camundongos Transgênicos , Neoplasias/metabolismo , Neoplasias/patologia , Oligonucleotídeos Antissenso/imunologia , Medicina de Precisão , Inibidores de Proteínas Quinases/farmacologia , Fator de Crescimento Transformador beta/genética , Fator de Crescimento Transformador beta/imunologia , Fator de Crescimento Transformador beta/metabolismoRESUMO
The use of bone morphogenetic protein-2 (rhBMP-2) in spinal fusion has increased dramatically since an FDA approval for its use in anterior lumbar fusion with the LT cage. There are several reports of its use in transforaminal lumbar interbody fusion, posterolateral fusion, and anterior cervical fusion. Reports on adverse effects of rhBMP-2 when used in spinal fusion are scarce in literature. An Institutional Review Board approved retrospective study was conducted in patients undergoing anterior spinal fusion and instrumentation following diskectomy at a single center. Forty-six consecutive patients were included. Twenty-two patients treated with rhBMP-2 and PEEK cages were compared to 24 in whom allograft spacers and demineralized bone matrix was used. Patients filled out Cervical Oswestry Scores, VAS for arm pain, neck pain, and had radiographs preoperatively as well at every follow up visit. Radiographic examination following surgery revealed end plate resorption in all patients in whom rhBMP-2 was used. This was followed by a period of new bone formation commencing at 6 weeks. In contrast, allograft patients showed a progressive blurring of end plate-allograft junction. Dysphagia was a common complication and it was significantly more frequent and more severe in patients in whom rhBMP-2 was used. Post operative swelling anterior to the vertebral body on lateral cervical spine X-ray was significantly larger in the rhBMP-2 group when measured from 1 to 6 weeks after which it was similar. These effects are possibly due to an early inflammatory response to rhBMP-2 and were observed to be dose related. With the parameters we used, there was no significant difference in the clinical outcome of patients in the two groups at 2 years. The cost of implants in patients treated with rhBMP-2 and PEEK spacers was more than three times the cost of allograft spacers and demineralized bone matrix in 1, 2, and 3-level cases. Despite providing consistently good fusion rates, we have abandoned using rhBMP-2 and PEEK cages for anterior cervical fusion, due to the side effects, high cost, and the availability of a suitable alternative.
Assuntos
Proteínas Morfogenéticas Ósseas/uso terapêutico , Vértebras Cervicais/cirurgia , Discotomia/efeitos adversos , Proteínas Recombinantes/uso terapêutico , Fusão Vertebral/efeitos adversos , Fator de Crescimento Transformador beta/uso terapêutico , Adulto , Idoso , Artrodese/efeitos adversos , Artrodese/métodos , Matriz Óssea , Proteína Morfogenética Óssea 2 , Proteínas Morfogenéticas Ósseas/efeitos adversos , Placas Ósseas/efeitos adversos , Vértebras Cervicais/diagnóstico por imagem , Transtornos de Deglutição/etiologia , Discotomia/economia , Discotomia/métodos , Feminino , Rouquidão/etiologia , Humanos , Fixadores Internos/efeitos adversos , Fixadores Internos/economia , Masculino , Pessoa de Meia-Idade , Dor Pós-Operatória/etiologia , Próteses e Implantes/efeitos adversos , Radiografia , Proteínas Recombinantes/efeitos adversos , Estudos Retrospectivos , Fusão Vertebral/economia , Fusão Vertebral/métodos , Fator de Crescimento Transformador beta/efeitos adversos , Transplante HomólogoRESUMO
BACKGROUND: Several recent in vitro and in vivo studies have reported the beneficial properties of gene delivery of therapeutic factors to the intervertebral disc, as a potential treatment strategy for degenerative disc disease; however, to date, no studies have assessed the safety and toxicity of the practical application of this treatment modality. PURPOSE: To assess the safety of inappropriately dosed or misdirected gene delivery to the spinal column in an in vivo model. STUDY DESIGN: The potential toxicity of gene therapy to the spinal column was assessed in this pilot study by monitoring clinical and histological changes in the spinal cord after intradural injections of an adenoviral vector containing the complementary deoxyribonucleic acid (cDNA) for potentially therapeutic factors in the treatment of degenerative disc disease. METHODS: Fourteen New Zealand White rabbits were divided into experimental groups to receive an intradural injection (<10 microL) of saline alone or saline in combination with recombinant transforming growth factor beta1 (TGF-beta1) or an adenoviral vector containing the cDNA for either TGF-beta1 (at previously established therapeutic or elevated concentrations) or bone morphogenic protein-2 (BMP-2). Animals were monitored clinically and spinal cords were harvested for histological analysis. RESULTS: No neurological deficits developed in any of the animals receiving injections of saline alone or saline in combination with the therapeutic dose of Ad-TGF-beta1, Ad-BMP-2, or with recombinant TGF-beta1. However, animals receiving a higher concentration of Ad-TGF-beta1 developed bilateral lower extremity paralysis with significant histological changes. CONCLUSIONS: Inappropriately dosed or directed gene delivery to the spinal column may result in significant complications. However, with appropriate dosing, a therapeutic window may exist where the potential benefits of gene therapy in the treatment of degenerative disc disease outweigh its risks.